logo

Sarepta Therapeutics (SRPT)



Trade SRPT now with
  Date
  Headline
10/15/2018 9:06:40 AM Sarepta And Lysogene Announce Exclusive License Agreement For LYS-SAF302
10/15/2018 8:02:12 AM Sarepta And Lysogene Announce License Agreement For LYS-SAF302
10/8/2018 8:31:08 AM Sarepta Therapeutics Enters Long-term Strategic Manufacturing Partnership With Paragon Bioservices
10/5/2018 8:33:53 AM Sarepta Announces Agreement With Nationwide Children’s Hospital For Rights To Its Gene Therapy Program
9/28/2018 6:05:30 PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/24/2018 7:03:04 AM Sarepta Announces Clinical Hold Lifted For Its Duchenne Muscular Dystrophy Micro-dystrophin Gene Therapy Program
9/21/2018 6:30:39 AM Sarepta Therapeutics Reports Negative CHMP Re-examination Opinion For Eteplirsen
8/20/2018 8:34:04 AM Sarepta Therapeutics Announces Recipients Of Route 79, The Duchenne Scholarship Program
8/8/2018 4:04:01 PM Sarepta Therapeutics Q2 Loss Per Share $1.67 Vs. $1.15 Per Share Last Year
8/8/2018 4:02:52 PM Sarepta Signs Long-term Strategic Investment And License Agreements With Lacerta
7/25/2018 4:34:53 PM Sarepta Therapeutics Says Phase 1/2a DMD Micro-Dystrophin Gene Therapy Trial Placed On Clinical Hold